Learning to walk ritual. She picks up the cell phone first, and then the computer mouse: overall, her future may include lots of talking on the phone and then love for computers.
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
The ICKEE Stikeez® invasion is here! The squishy, squeezy, sticky, collectible figures known as ICKEE Stikeez from Zing® Toys are now available at select specialty toy stores nationwide.
The first collection of ICKEE Stikeez (#IckeeStikeez) has 24 whimsical, wacky and hilariously disgusting characters. Each of the characters sit on a suction cup that enables the ICKEEZ to stick to any flat surface, such as lockers, lunchboxes, windows and cell phones. When pulled-off, the ICKEEZ make a cool, loud “pop”! Characters come in PODZ that are reminiscent of vending machine capsules, which also have built-in play. Kids can connect them to create various structures and environments for their ICKEE Stikeez characters.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52105-ickee-stickeez-zing-toys-innovation-play-holiday-collectible-suction-cup
Handheld Group, a leading manufacturer of rugged mobile computers, today announced the new Nautiz X2 enterprise handheld which integrates a high-quality scanner, camera and mobile phone while offering the most compact and ergonomic form factor on the market.
The Nautiz X2 gives enterprise users an all-in-one mobile computer that can handle all the tasks of a day’s work, with built-in ruggedness that allows it to be used anywhere from a warehouse to challenging outdoor environments with moisture, dust, extreme high or low temperatures and potential drops.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7832051-handheld-launches-nautiz-x2-rugged-android/
Unfortunately, as Graham is adopted, he doesn\\\'t have an HLA-identical sibling to act as a donor for him. So the Red Cross here in Australia searched the Bone Marrow Registries worldwide for 9 months to find a match.
Graham has a rare tissue type and a match was not found.
Thanks to generous donations of over $400,000, Graham was able to travel from his home in Melbourne, Australia to Seattle in the USA for a revolutionary, life-saving stem cell treatment in April 2008.
On Wed 6th August, he was the 8th person in the world to receive a Stem Cell Transplant using stem cells grown in the lab from an umbilical cord.
The treatment was a complete success and he is now leukaemia free.
He is back in Melbourne, recovering from the treatment but still has outstanding medical bills of $416,000.
http://www.freecellservicestore.com Why pay for your mobile phone service when your can get it Free? Learn how to stop paying your phone bill and start paying yourself!
